Longevity Insights & Analysis

Skiers call it being 'over your skis,' leaning downhill faster than your technique can support. That's the modern longevity peptide movement. The biology isn't fake; it's often elegant and directionally sound. But BPC-157 and its 'bio-regulatory' cousins have outrun their evidence. No lifespan data, no established mechanism, no long-term safety studies, just mechanistic storytelling mistaken for proof. Naturalness isn't safety. Mechanism isn't validation.

The New York Times' recent testosterone piece got the biology right but buried it under manosphere pop psychology. As a physician who's prescribed TRT for decades, I've seen the benefits firsthand — but the article missed the real story: total testosterone is a misleading metric, free testosterone is what matters, and this hormone isn't just about libido or muscle. It's a human function hormone, tied to inflammation, immunity, and healthspan itself.

Most doctors treat uACR as a routine kidney test. The data tells a different story. This biomarker may be one of the clearest windows into vascular aging we have — and risk starts rising long before anything looks "abnormal."

For decades the Women’s Health Initiative shaped how we view hormone therapy. The HRT timing hypothesis explained why benefits appear in younger menopausal women but not later. Emerging research suggests estrogen may protect cardiovascular health by preserving the endothelial glycocalyx, supporting arterial resilience and preventing early vascular damage before it becomes irreversible.

Plasmalogens are clearly depleted in aging and Alzheimer’s—but whether that depletion drives disease or reflects downstream dysfunction remains unresolved. This piece argues for a balanced, evidence-based middle ground: acknowledge biological plausibility and early biochemical signals, reject overstated clinical claims, and integrate emerging interventions cautiously within a framework of vascular optimization, transparency, and disciplined scientific curiosity.

The endothelial glycocalyx is a fragile sugar rich layer that lines blood vessels and may be one of the earliest drivers of vascular aging. Long before plaques form or blood pressure rises, damage to this protective surface can impair nitric oxide signaling, increase arterial stiffness, and amplify inflammation. Understanding and supporting glycocalyx health may offer a more upstream approach to preventing cardiovascular disease.